Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) changed by 0.00% from its latest closing price compared to the recent 1-year high of $3.50. The company’s stock price has collected -13.53% of loss in the last five trading sessions. Press Release reported on 06/07/21 that Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat’s Safety, Dosing, and Drug Activity at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Is It Worth Investing in Salarius Pharmaceuticals Inc. (NASDAQ :SLRX) Right Now?
Plus, the 36-month beta value for SLRX is at 1.57. Opinions of the stock are interesting as 2 analysts out of 2 who provided ratings for Salarius Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $4.40. SLRX currently public float of 44.00M and currently shorts hold a 3.80% ratio of that float. Today, the average trading volume of SLRX was 1.61M shares.
SLRX’s Market Performance
SLRX stocks went down by -13.53% for the week, with a monthly drop of -4.96% and a quarterly performance of -22.82%, while its annual performance rate touched -27.67%. The volatility ratio for the week stands at 11.19% while the volatility levels for the past 30 days are set at 10.15% for Salarius Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -10.02% for SLRX stocks with a simple moving average of -1.65% for the last 200 days.
Analysts’ Opinion of SLRX
Many brokerage firms have already submitted their reports for SLRX stocks, with Ladenburg Thalmann repeating the rating for SLRX by listing it as a “Buy.” The predicted price for SLRX in the upcoming period, according to Ladenburg Thalmann is $3.80 based on the research report published on April 27th of the previous year 2020.
SLRX Trading at -10.70% from the 50-Day Moving Average
After a stumble in the market that brought SLRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.14% of loss for the given period.
Volatility was left at 10.15%, however, over the last 30 days, the volatility rate increased by 11.19%, as shares sank -4.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.86% lower at present.
During the last 5 trading sessions, SLRX fell by -13.53%, which changed the moving average for the period of 200-days by +19.00% in comparison to the 20-day moving average, which settled at $1.2755. In addition, Salarius Pharmaceuticals Inc. saw 26.37% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at SLRX starting from HANISH ARNOLD C, who purchase 4,000 shares at the price of $0.98 back on Aug 21. After this action, HANISH ARNOLD C now owns 11,350 shares of Salarius Pharmaceuticals Inc., valued at $3,920 using the latest closing price.
Arthur David J., the Chief Executive Officer of Salarius Pharmaceuticals Inc., purchase 2,000 shares at $1.01 during a trade that took place back on Aug 19, which means that Arthur David J. is holding 2,000 shares at $2,020 based on the most recent closing price.
Stock Fundamentals for SLRX
Current profitability levels for the company are sitting at:
- -148.78 for the present operating margin
The net margin for Salarius Pharmaceuticals Inc. stands at -140.49. The total capital return value is set at -46.18, while invested capital returns managed to touch -44.91. Equity return is now at value -27.70, with -25.60 for asset returns.
Based on Salarius Pharmaceuticals Inc. (SLRX), the company’s capital structure generated 2.15 points at debt to equity in total, while total debt to capital is 2.11.
When we switch over and look at the enterprise to sales, we see a ratio of 0.68, with the company’s debt to enterprise value settled at 0.13. The receivables turnover for the company is 2.71 and the total asset turnover is 0.27. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.70.